Sponsor Pipeline

OBI Pharma, Inc Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
4
Active Trials
2
Recruiting
1
Phase 3
4
Disease Areas
Active Trials by Phase
Phase 3
1
Phase 2
1
Phase 1/2
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT03562637 Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With… Triple Negative Breast Cancer Active, Not Recruiting
Phase 2
NCT05442060 To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With… Non-small Cell Lung Cancer Recruiting
Phase 1/2
NCT07124117 A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors Advanced Solid Tumor Recruiting
NCT06480240 A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors Advanced Solid Tumor Active, Not Recruiting
Disease Areas
Breast Cancer (1) Triple-Negative Breast Cancer (1) Non-Small Cell Lung Cancer (NSCLC) (1) Lung Cancer (1)
Get alerts when OBI Pharma, Inc's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free